Mojun Zhu

WinnMed — United States

Medicine · Health Sciences

7h-index391citations111works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(34), Gastric Cancer Management and Outcomes(30), Pancreatic and Hepatic Oncology Research(28), Esophageal Cancer Research and Treatment(27), Cancer Genomics and Diagnostics(25)

Publications111 total

Immune related adverse events (irAEs) in Lynch vs non-Lynch microsatellite instability-high (MSI-high) gastrointestinal (GI) cancers: A retrospective cohort study.
Journal of Clinical Oncology·2026
Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.
Journal of Clinical Oncology·2026
Immunotherapy in Synchronous Gastric and Colonic Deficient Mismatch Repair Malignancies in a Case Series of Patients With Lynch Syndrome
JCO Precision Oncology·2026
Translational Relevance of the Genomic Landscape of KRASG12D-Mutant Colorectal and Pancreatic Cancers
Targeted Oncology·2025
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025Open Access
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025Open Access
PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study
JCO oncology advances.·2025Open Access
398 Real-time discovery of neoantigen-specific TCR clonotypes reveals variable CD8+ T cell functional states in patients with KRAS-mutant colorectal cancer
Regular and Young Investigator Award Abstracts·2025Open Access
Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic
JCO Precision Oncology·2025· 1 cited
Tu1481: CLINICAL AND PATHOLOGIC OUTCOMES IN MSI-HIGH GASTROESOPHAGEAL CANCERS
Gastroenterology·2025
Supplementary Table S2 from Identification of Candidate Alterations Mediating <i>KRAS</i><sup>G12C</sup> Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Identification of Candidate Alterations Mediating <i>KRAS</i> G12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
Clinical Cancer Research·2025· 7 citedOpen Access
Supplementary Table S5 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Figure S3 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Table S3 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Figure S1 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Table S1 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Figure S2 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Supplementary Table S4 from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
Data from Identification of Candidate Alterations Mediating &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
2025Open Access
page 1 of 6Next →

Frequent Co-authors

Harry H. Yoon(19), Robert R. McWilliams(18), Tanios Bekaii‐Saab(15), Katrina S. Pedersen(13), Wen Wee(12), Daniel H. Ahn(12), Haidong Dong(11), Nathan R. Foster(10), Joleen M. Hubbard(10), Hao Xie(9), Andrea Wang‐Gillam(7), Rama Suresh(7), A. Craig Lockhart(7), Amberly Brown(7), John M. Herndon(7), Benjamin Tan(7), Mina Abdiannia(7), Nikolaos A. Trikalinos(7), Lee Ratner(7), Olivia Aranha(7)